To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in South Korea

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

224 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-02-28

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a National, Multicentre, Observational Registry to study Adherence and Long Term Outcomes of Therapy in paediatric subjects using easypod™ electromechanical device for growth hormone treatment from hospital in Korea in order to assess the level of adherence of subjects receiving SAIZEN® via easypod™.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in the UK

NCT01263457

Growth Disorders

COMPLETED

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in France

NCT01291394

Growth Disorders

COMPLETED

Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ Electromechanical Device for Growth Hormone Treatment

NCT01438528

Growth Disorders

COMPLETED

Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Czech Republic

NCT01400997

Growth Disorders

COMPLETED

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ (ECOS Taiwan, Indonesia, Singapore)

NCT02015273

Growth Disorders

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects will be enrolled in a multicenter, longitudinal, observational registry. Parents/subjects will provide their Informed Consent/assent to upload their data for population-based analyses and optionally to adhere to a patient adherence support program designed to improve their adherence and, ultimately, clinical outcomes. Adherence data will be primarily derived from the easypod™ device combined with physician data entry of outcome measures. Data will be collected retrospectively and prospectively. This will allow the establishment of adherence profiles and explore the hypothesis that patient adherence support programs improve adherence and subsequent clinical outcomes. Collected data will be also analyzed in a multinational pooled analysis of comparable national studies.

Primary Objective:

To assess the level of adherence of subjects receiving SAIZEN via easypod™

Secondary Objectives:

* To describe the impact of adherence on clinical outcomes for subject receiving SAIZEN via easypod™
* To identify adherence subject profiling
* To assess the impact of adherence on Insulin-like growth factor 1 (IGF-1) (i.e. above, below or within normal ranges)
* Temporal profile of IGF-1 and IGFBP-3 levels

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Growth Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Administered growth hormone via the easypod™ electromechanical device according to Summary of Product Characteristics (SmPC)
* Over the age of \>2 years
* Under \<18 years of age, or over 18 without fusion of growth plates
* Parent's or guardian's written informed consent, given before entering data into the registry, with the understanding that the subject or parent/guardian may withdraw consent at any time without prejudice to future medical care. If the child is old enough to read and write, a separate assent form will be given as defined in the appropriate jurisdiction of each country.

Exclusion Criteria

* Subjects taking growth hormone in whom growth plates have fused (i.e. for taking growth hormone for it's metabolic effects)
* Contra-indications to SAIZEN® as defined in the Summary of Product Characteristics (SmPC)
* Use of an investigational drug or participation in an interventional clinical study

Minimum Eligible Age

2 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No